Sign in to view content

Brolucizumab for Neovascular AMD: The 2 Year HAWK and HARRIER Results

Pravin U. Dugel, MD

Video
Published 2018

Related

VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more